# An Extension Study to Learn About the Long-Term Safety of Fazirsiran and if Fazirsiran Can Help People With Alpha-1 Antitrypsin Liver Disease

> **NCT05899673** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Takeda** · enrollment: 31 (actual)

## Conditions studied

- Alpha1-Antitrypsin Deficiency

## Interventions

- **DRUG:** Fazirsiran Injection

## Key facts

- **NCT ID:** NCT05899673
- **Lead sponsor:** Takeda
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-08-08
- **Primary completion:** 2033-05-02
- **Final completion:** 2033-05-02
- **Target enrollment:** 31 (ACTUAL)
- **Last updated:** 2025-10-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05899673

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05899673, "An Extension Study to Learn About the Long-Term Safety of Fazirsiran and if Fazirsiran Can Help People With Alpha-1 Antitrypsin Liver Disease". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05899673. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*